The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

Hdl Handle:
http://hdl.handle.net/10147/264001
Title:
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
Authors:
Treacy, Maxwell P; Hurst, Tara P
Citation:
BMC Ophthalmology. 2012 Sep 02;12(1):46
Issue Date:
2-Sep-2012
URI:
http://dx.doi.org/10.1186/1471-2415-12-46; http://hdl.handle.net/10147/264001
Abstract:
Abstract Background Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs. Discussion Based on the evidence of large-scale clinical studies investigating the systemic administration of fenofibrate, this ligand for peroxisome proliferator-activated receptor-α is potentially a good candidate for intraocular delivery. Here, we describe the mechanisms by which it might be acting to improve diabetic retinopathy, its relative safety and we speculate on how it could be developed for intraocular delivery. Summary In this paper, we provide a rationale for the further investigation of peroxisome proliferator-activated receptor-α agonists as intraocular agents for the treatment of diabetic retinopathy.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorTreacy, Maxwell P-
dc.contributor.authorHurst, Tara P-
dc.date.accessioned2013-01-02T16:06:26Z-
dc.date.available2013-01-02T16:06:26Z-
dc.date.issued2012-09-02-
dc.identifier.citationBMC Ophthalmology. 2012 Sep 02;12(1):46-
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2415-12-46-
dc.identifier.urihttp://hdl.handle.net/10147/264001-
dc.description.abstractAbstract Background Systemic therapeutics targeting the peroxisome proliferator-activated receptors have been found to be beneficial in the treatment of diabetic retinopathy. In this paper, we provide a rationale for the use of these therapeutics as intraocular agents. In addition, we introduce the peroxisome proliferator-activated receptors and describe their functions in response to the drugs. Discussion Based on the evidence of large-scale clinical studies investigating the systemic administration of fenofibrate, this ligand for peroxisome proliferator-activated receptor-α is potentially a good candidate for intraocular delivery. Here, we describe the mechanisms by which it might be acting to improve diabetic retinopathy, its relative safety and we speculate on how it could be developed for intraocular delivery. Summary In this paper, we provide a rationale for the further investigation of peroxisome proliferator-activated receptor-α agonists as intraocular agents for the treatment of diabetic retinopathy.-
dc.titleThe case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderMaxwell P Treacy et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2012-12-28T20:07:24Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.